Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
1
20%
Ph phase_3
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

unknown120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

NCT02576847
unknownphase_2

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

NCT03688971
completedphase_2

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

NCT03091426
completedphase_1

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

NCT03071679
completedphase_2

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133

Clinical Trials (5)

Showing 5 of 5 trials
NCT02576847Phase 3

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

Completed
NCT03688971Phase 2

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Unknown
NCT03091426Phase 2

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Completed
NCT03071679Phase 1

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Completed
NCT01784133Phase 2

A Twelve Week Safety and Efficacy Study in Rosacea

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5